PCA
LXRX icon

Pallas Capital Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Pallas Capital Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-36,765
Closed -$34.8K – 925
2025
Q2 		$34.8K Buy
36,765
+557
+2% +$361 ﹤0.01% 838
2025
Q1 		$16.7K Buy
+36,208
New +$22.8K ﹤0.01% 748

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pallas Capital Advisors's LXRX Position: Q3 2025 in Review

Pallas Capital Advisors sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2025, closing a stake of 36,765 shares — an estimated $34.8K sold.

Pallas Capital Advisors first reported a position in LXRX in Q1 2025 and held it in 2 quarters. The position peaked at $34.8K in Q2 2025. 123 funds tracked by Wall St. Rank hold LXRX as of Q3 2025.

  • Pallas Capital Advisors reported no remaining Lexicon Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Pallas Capital Advisors sold 36,765 Lexicon Pharmaceuticals shares in Q3 2025, an estimated $34.8K.
  • Pallas Capital Advisors first reported a position in Lexicon Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Pallas Capital Advisors's Lexicon Pharmaceuticals position peaked at $34.8K in Q2 2025.
  • 123 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2025.

Based on Pallas Capital Advisors's 13F filing for Q3 2025, filed 7 Nov 2025.